Metrics as of 10/16/2026, 12:55 PM (Berlin time), refresh in progress.
Esperion Therapeutics Stock
Esperion Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Sheldon L. Koenig
- Employees
- 294
- Market cap
- $661 M
- IPO
- 26/06/2013
Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet…
Esperion Therapeutics stock: price history
1D
+0.0%
1W
+0.6%
1M
+1.0%
6M
-3.6%
YTD
-14.1%
1Y
+169.5%
2Y
+26.7%
5Y
-83.5%
10Y
-71.5%
Next earnings date
Next earnings date
No date known
Volatility around earnings
~16% stronger price swings than usual
Ask the agents about Esperion Therapeutics
Analyst assessment of Esperion Therapeutics
PRICE TARGET LOW
US$3.16
CONSENSUS
US$3.19
MEDIAN
US$3.16
PRICE TARGET HIGH
US$3.28
0
STRONG BUY
8
BUY
15
HOLD
2
SELL
0
STRONG SELL
25
TOTAL · Hold
As of: 04/05/2026
Esperion Therapeutics stock metrics
P/E
-131.4
P/B
-2.6
EV/EBITDA
26.29
RETURN ON EQUITY
8.2%
NET MARGIN
-31.5%
DEBT/EQUITY
-1.77
DIVIDEND YIELD
0.0%
AS OF
31/03/2026
Free float & liquidity
FREE FLOAT
100.0%
FLOAT SHARES
207,908,719
AVG. DAILY VOLUME (30D)
14,169,754
Institutional holders
Comparable stocks
Frequently asked questions about Esperion Therapeutics stock
What does Esperion Therapeutics do?
Esperion Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Sheldon L. Koenig, the company employs around 294 people.
The IPO was on 26/06/2013; the stock trades on NASDAQ under the ticker ESPR.
What do analysts say about Esperion Therapeutics stock?
25 analysts rate the stock, the consensus is Hold (as of 04/05/2026).
The average price target is US$3.19, ranging from US$3.16 to US$3.28, with a median of US$3.16.
This is an external assessment, not a statement by Market Jury.
When does Esperion Therapeutics report next?
Around past earnings, price swings were roughly 16% stronger than usual.
Does Esperion Therapeutics pay a dividend?
No, Esperion Therapeutics currently does not pay a dividend.
Which stocks are comparable to Esperion Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Esperion Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Esperion Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.